

# Cytomegalovirus Infection in People Living with HIV: Our Experience

Authors :**Salem Smail**, Sofia Sarrah, Imen Nadjaoui, Amel Mechehat, Ilhem Chettab, Basma Redjil, Ryma Boutouha, Asma Djadour, Sarah Bensaadi, Amel Boudine, Fayza Belkacemi, Assia Dai, Mohamed Zeroual, Nassima Belabas

14<sup>e</sup> JOURNÉE  
DE LA SAMIC



31 Mai et 1<sup>er</sup> Juin 2025 - Hôtel El Aurassi, Alger

4<sup>e</sup> CONGRÈS  
INTERNATIONAL

# Background

- Cytomegalovirus (CMV) is a **double-stranded DNA virus** belonging to the **herpes virus** family ( $\beta$  Herpesvirus).
- CMV infection is usually benign in immunocompetent individuals but **remains latent indefinitely**.
- CMV infection remains a **major opportunistic infection** in people living with HIV (PLWHIV) with severe immunosuppression ( $CD4 < 100$ ), and causes **various organ impairments (CMV disease)**., leading to significant morbidity, mortality, and severe sequelae.
- Asymptomatic CMV reactivation is conventionally referred as "**CMV infection**" and **often precedes CMV disease**.

## objective

- The objective of this study is to analyze the **clinical, biological, and evolutionary characteristics of CMV infection in PLWHIV**.


## Patients and Methods

- **Retrospective study**
- **31 PLWHIV** hospitalized in an infectious disease department in Algiers are included between **January 1, 2014, and December 31, 2024**, for **confirmed or suspected CMV disease based on classic manifestations**.
- Analysis based on PLWHIV records for **clinical, biological, and progression characteristics under specific anti-CMV treatment**.

## Patient Characteristics (N=31)

<b>Average age</b>	<b>44 years</b>
<b>Sex ratio</b>	<b>1.58</b>
<b>Average CD4 count</b>	<b>38 (2-94) cells/mm<sup>3</sup></b>
<b>Average HIV plasma viral load</b>	<b>5.3 LOG10</b>
<b>Average CMV plasma viral load</b>	<b>3.5 LOG10 (N=16)</b>


## CMV Plasma Viral Load



## Association with Opportunistic Co-infections

<b>Tuberculosis</b>	<b>07</b>
<b>Pneumocystosis</b>	<b>04</b>
<b>Toxoplasmosis</b>	<b>01</b>
<b>Lymphoma</b>	<b>02</b>
<b>Kaposi Sarcoma</b>	<b>01</b>
<b>Total</b>	<b>15</b>

## Distribution of Organics damage




## Management and progression of patients


### Anti-CMV Medications Used (31)

GANCICLOVIR	64%
VALGANCICLOVIR	22%
FOSCARNET	9.6%

### Evolution




### Sequelae Distribution




- Blindness
- Visual impairment
- neurologique

# Retinal angiography

Right eye = normal



Left eye = pathologic



Sequelae of acute retinal necrosis with ischemic retinopathy in patient from the study

## Discussion 1 : Study Population and Immunological Vulnerability

- CMV infection **remains a frequent** opportunistic infection in PLWHIV in **our country**,
- It occurs mainly in **young adults** with an **average age of 44 years**.
- The occurrence of CMV disease **correlates with profound immunosuppression (average CD4 count: 38/mm<sup>3</sup>)**. The patient profile needs further study (late HIV diagnosis, non-adherence, discontinuation of care).
- **AIDS-defining opportunistic infection (OI) revised CDC 1993 classification** .



## Discussion 2: Dominant Clinical Manifestations

- **CMV retinitis is the most common form (64%)**, reinforcing its major role in CMV-related morbidity in uncontrolled PLWHIV.
- **Neurological and gastrointestinal involvement (19% and 10%, respectively)** highlight the **systemic nature of CMV**.
- **Macrophage activation syndrome(MAS)**, though rare (6%), is a **severe complication with high mortality**.

# CMV retinitis and risk of IRIS

## TERMINOLOGY

- **IRIS:** Immune Reconstitution Inflammatory Syndrome
- A phenomenon observed in PLWHIV following the initiation of antiretroviral therapy (ART), characterized by an excessive inflammatory response due to immune reconstitution."
- **Paradoxical IRIS:** Refers to the worsening of a previously diagnosed disease after ART initiation.
- **Unmasking IRIS:** Refers to the appearance of a previously undiagnosed disease following ART initiation.

## RECOMMENDATIONS

- Clinicians should not initiate ART immediately in patients with known or strongly suspected CMV retinitis
- Clinicians should refer patients with HIV who have CD4 counts  $<100$  cells/mm<sup>3</sup> but without known or suspected CMV for funduscopy
- Clinicians should ensure that after initiating ART, patients with a history of CMV retinitis are monitored by funduscopy

## Discussion 3: Association with Opportunistic Co-infections

- There is a **strong association** with **tuberculosis** (7 cases), **pneumocystosis** (4 cases), and **lymphoma** (2 cases).
- Profound immunosuppression often leads to **CMV being associated with multiple simultaneous opportunistic infections**, complicating diagnosis and management and making the prognosis uncertain.

## Discussion 4: Role of CMV Plasma Viral Load in Diagnosis

- CMV PCR (CMV DNA) was evaluated in only **16 PLWHIV** Due to reagent **unavailability** .
- The **average** plasma CMV viral load was **3.5 log**, suggesting a **correlation with CMV disease**. However negative CMV PCR does not rule out diagnosis (4 patients had negative CMV PCR).
- Routine CMV PCR testing for PLWHIV with CD4 <100 is essential to initiate **preemptive treatment**.

## Discussion 5:Therapeutic Evaluation and Patient Outcomes

- **Ganciclovir** (64%), **valganciclovir** (19%), and **foscarnet** (9.6%) are the specific treatments used.
- **The mortality rate of 16%** highlights the severity of these infections and the need for **early diagnosis and intervention**.
- About **45% of PLWHIV developed sequelae**, predominantly **blindness (46% of cases)**, reinforcing the importance of early **screening and preemptive treatment for CMV retinitis**.

## Conclusion & Recommendations

Reducing the incidence of CMV disease and its negative impact in PLWHIV requires:

- **Early detection and treatment of HIV infection**
- **Systematic screening and early treatment of CMV retinitis** via fundoscopy in PLWHIV with CD4 <100
- **Screening for CMV infection using CMV PCR** in PLWHIV with CD4 <100 and initiating preemptive treatment before organ involvement
- **Development of more effective anti-CMV drugs** with less of adverse effects and refinement of diagnostic strategies

Thank you for your attention